Fortress Biotech

FBIO

----

Current ValuationThe current P/E ratio is 0.63, above the reasonable range, cheaper than 8.29% of the time in the past 5 years, and the industry ranks 7/605, the industry Median -1.93.

0.626xP/E

Stock price$1.94Earnings per share$3.10

Historical Valuation

P/E ratioTypical rangeMedian

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.

021426384

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.

0x30x60x90x120x150x

P/E ratio
Name/Symbol
INCYUSIncyte	14.26x	70.39%	$22.99B
GRFSUSGRIFOLS SA	9.84x	42.44%	$5.16B
ACADUSAcadia Pharma	9.14x	73.21%	$3.48B
NRIXUSNurix Therapeutics	9.64x	191.12%	$2.84B
PURRUSHyperliquid Strategies	10.45x	67.60%	$2.68B
ADMAUSAdma Biologics	14.60x	35.42%	$2.47B
AUPHUSAurinia Pharma	7.16x	54.20%	$2.25B
LKFTUSLakefront Biotherapeutics	2.84x	86.45%	$1.96B
ANABUSAnaptysbio	5.47x	1,003.56%	$1.43B
VORUSVor BioPharma	1.78x	89.71%	$1.12B
MGTXUSMeiraGTx	11.99x	122.03%	$946.98M
BVNRYUSBavarian Nordic A/S	3.84x	--	$919.84M
RIGLUSRigel Pharma	2.84x	83.91%	$913.07M
ABUSUSArbutus Pharma	5.38x	535.59%	$823.21M
IRWDUSIronwood Pharma	4.52x	715.55%	$586.60M
AGENUSAgenus	3.14x	--	$288.13M
CUVLUSClinuvel Pharmaceuticals	11.24x	--	$258.19M
QTTBUSQ32 Bio	7.64x	162.04%	$258.10M
PLXUSProtalix Biotherap	10.93x	400.00%	$207.07M
CGENUSCompugen	5.71x	173.68%	$200.82M

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.